Title: A Prospective, Open, Non-controlled Clinical Investigation to Evaluate the Performance and Safety of an Antimicrobial Foam Transferring Dressing in Patients With Malignant Wounds
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Malignant Wounds
- Sponsor
- Molnlycke Health Care AB
- Enrollment
- 14
- Locations
- 2
- Primary Endpoint
- Infection in the Wound (Signs of Clinical Infection)
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
This is a prospective, open, non-controlled clinical investigation to evaluate the performance and safety of using Mepilex Transfer Ag on a malignant wound. Approximately ten to fifteen (10-15) subjects from one to three centers in Europe, presenting with a malignant (fungating) wound will be enrolled into the study. Eligible subjects will have one malignant (fungating) wound selected as a "study site". Subjects will be followed for a one-week observation period with their existing product followed by a 4-week investigation period using Mepilex Transfer Ag.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Presence of at least one exuding malignant (fungating) wound in need for antimicrobial treatment
- •Both genders with an age ≥ 18 years at randomization
- •Subjects with a suspected survival time of \> 3 months
- •Signed informed consent
Exclusion Criteria
- •Any known or suspected systemic infection
- •Use of metronidazole is not allowed during the investigation period
- •Any known sensitivity to silver or other components/products used in this study.
- •Major uncontrolled systemic disorders such as hepatic, renal, neurologic, or endocrinologic disorders.
- •Participation in another investigational study while participating in this study.
Outcomes
Primary Outcomes
Infection in the Wound (Signs of Clinical Infection)
Time Frame: weekly, for 5 weeks
Weekly Visual inspection of the wounds by the investigators.